Skip to main content
Top
Published in: BMC Medical Research Methodology 1/2017

Open Access 01-12-2017 | Research article

Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study

Authors: In Sung Cho, Ye Rin Chae, Ji Hyeon Kim, Hae Rin Yoo, Suk Yong Jang, Gyu Ri Kim, Chung Mo Nam

Published in: BMC Medical Research Methodology | Issue 1/2017

Login to get access

Abstract

Background

Aspirin has been considered to be beneficial in preventing cardiovascular diseases and cancer. Several pharmaco-epidemiology cohort studies have shown protective effects of aspirin on diseases using various statistical methods, with the Cox regression model being the most commonly used approach. However, there are some inherent limitations to the conventional Cox regression approach such as guarantee-time bias, resulting in an overestimation of the drug effect. To overcome such limitations, alternative approaches, such as the time-dependent Cox model and landmark methods have been proposed. This study aimed to compare the performance of three methods: Cox regression, time-dependent Cox model and landmark method with different landmark times in order to address the problem of guarantee-time bias.

Methods

Through statistical modeling and simulation studies, the performance of the above three methods were assessed in terms of type I error, bias, power, and mean squared error (MSE). In addition, the three statistical approaches were applied to a real data example from the Korean National Health Insurance Database. Effect of cumulative rosiglitazone dose on the risk of hepatocellular carcinoma was used as an example for illustration.

Results

In the simulated data, time-dependent Cox regression outperformed the landmark method in terms of bias and mean squared error but the type I error rates were similar. The results from real-data example showed the same patterns as the simulation findings.

Conclusions

While both time-dependent Cox regression model and landmark analysis are useful in resolving the problem of guarantee-time bias, time-dependent Cox regression is the most appropriate method for analyzing cumulative dose effects in pharmaco-epidemiological studies.
Literature
1.
go back to reference Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians study. N Engl J Med. 1989;321:129–35.CrossRef Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing physicians study. N Engl J Med. 1989;321:129–35.CrossRef
2.
go back to reference Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.CrossRefPubMed Berger JS, Roncaglioni MC, Avanzini F, Pangrazzi I, Tognoni G, Brown DL. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA. 2006;295(3):306–13.CrossRefPubMed
3.
go back to reference Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266(4):521–7.CrossRef Manson JE, Stampfer MJ, Colditz GA, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of aspirin use and primary prevention of cardiovascular disease in women. JAMA. 1991;266(4):521–7.CrossRef
4.
go back to reference Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation. 2010;121(24):2694–701.CrossRefPubMed Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, Rosenson RS, Williams CD, Wilson PW, Kirkman MS. Aspirin for primary prevention of cardiovascular events in people with diabetes. Circulation. 2010;121(24):2694–701.CrossRefPubMed
5.
go back to reference Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304.CrossRefPubMed Ridker PM, Cook NR, Lee I-M, Gordon D, Gaziano JM, Manson JE, Hennekens CH, Buring JE. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med. 2005;352(13):1293–304.CrossRefPubMed
6.
go back to reference Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209–16.CrossRefPubMed Seshasai SRK, Wijesuriya S, Sivakumaran R, Nethercott S, Erqou S, Sattar N, Ray KK. Effect of aspirin on vascular and nonvascular outcomes: meta-analysis of randomized controlled trials. Arch Intern Med. 2012;172(3):209–16.CrossRefPubMed
7.
go back to reference Hwang I-C, Jeon J-Y, Kim Y, Kim HM, Yoon YE, Lee S-P, Kim H-K, Sohn D-W, Sung J, Kim Y-J. Association between aspirin therapy and clinical outcomes in patients with non-obstructive coronary artery disease: a cohort study. PLoS One. 2015;10(6):e0129584.CrossRefPubMedPubMedCentral Hwang I-C, Jeon J-Y, Kim Y, Kim HM, Yoon YE, Lee S-P, Kim H-K, Sohn D-W, Sung J, Kim Y-J. Association between aspirin therapy and clinical outcomes in patients with non-obstructive coronary artery disease: a cohort study. PLoS One. 2015;10(6):e0129584.CrossRefPubMedPubMedCentral
8.
go back to reference Ofman P, Petrone AB, Peralta A, Hoffmeister P, Albert CM, Djousse L, Gaziano JM, Rahilly-Tierney CR. Aspirin Use and Risk of Atrial Fibrillation in the Physicians' Health Study. J Am Heart Assoc. 2014;3(4):e000763.CrossRefPubMedPubMedCentral Ofman P, Petrone AB, Peralta A, Hoffmeister P, Albert CM, Djousse L, Gaziano JM, Rahilly-Tierney CR. Aspirin Use and Risk of Atrial Fibrillation in the Physicians' Health Study. J Am Heart Assoc. 2014;3(4):e000763.CrossRefPubMedPubMedCentral
9.
go back to reference Ekström N, Cederholm J, Zethelius B, Eliasson B, Fhärm E, Rolandsson O, Miftaraj M, Svensson A-M, Gudbjörnsdottir S. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open. 2013;3(4):e002688.CrossRefPubMedPubMedCentral Ekström N, Cederholm J, Zethelius B, Eliasson B, Fhärm E, Rolandsson O, Miftaraj M, Svensson A-M, Gudbjörnsdottir S. Aspirin treatment and risk of first incident cardiovascular diseases in patients with type 2 diabetes: an observational study from the Swedish National Diabetes Register. BMJ Open. 2013;3(4):e002688.CrossRefPubMedPubMedCentral
10.
go back to reference King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke. 2013;44(2):542–6.CrossRefPubMed King A, Shipley M, Markus H, Investigators A. The effect of medical treatments on stroke risk in asymptomatic carotid stenosis. Stroke. 2013;44(2):542–6.CrossRefPubMed
11.
go back to reference Azoulay L, Dell’Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case–control study. BMC Cardiovasc Disord. 2012;12(1):49.CrossRefPubMedPubMedCentral Azoulay L, Dell’Aniello S, Simon TA, Langleben D, Renoux C, Suissa S. A net clinical benefit analysis of warfarin and aspirin on stroke in patients with atrial fibrillation: a nested case–control study. BMC Cardiovasc Disord. 2012;12(1):49.CrossRefPubMedPubMedCentral
12.
go back to reference Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The lancet oncology. 2009;10(5):501–7.CrossRefPubMed Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P, Jankowski J, La Vecchia C, Meyskens F, Senn HJ. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. The lancet oncology. 2009;10(5):501–7.CrossRefPubMed
13.
go back to reference Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med. 2007;146(5):365–75.CrossRefPubMed Dubé C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, Sampson M, Moher D. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the US Preventive Services Task Force. Ann Intern Med. 2007;146(5):365–75.CrossRefPubMed
14.
go back to reference Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 1997;94(7):3336–40.CrossRefPubMedPubMedCentral Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci. 1997;94(7):3336–40.CrossRefPubMedPubMedCentral
15.
go back to reference Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, RN DB. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705–16.CrossRefPubMed Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, RN DB. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93(5):705–16.CrossRefPubMed
16.
go back to reference Fraser D, Sullivan F, Thompson A, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623–7.CrossRefPubMedPubMedCentral Fraser D, Sullivan F, Thompson A, McCowan C. Aspirin use and survival after the diagnosis of breast cancer: a population-based cohort study. Br J Cancer. 2014;111(3):623–7.CrossRefPubMedPubMedCentral
17.
go back to reference Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608–15.CrossRefPubMed Jacobs EJ, Thun MJ, Bain EB, Rodriguez C, Henley SJ, Calle EE. A large cohort study of long-term daily use of adult-strength aspirin and cancer incidence. J Natl Cancer Inst. 2007;99(8):608–15.CrossRefPubMed
18.
go back to reference Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer. 2015;15(1):911.CrossRefPubMedPubMedCentral Mc Menamin ÚC, Cardwell CR, Hughes CM, Murray LM. Low-dose aspirin and survival from lung cancer: a population-based cohort study. BMC Cancer. 2015;15(1):911.CrossRefPubMedPubMedCentral
19.
go back to reference Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case–control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700–8. e702CrossRefPubMed Cardwell CR, Kunzmann AT, Cantwell MM, Hughes C, Baron JA, Powe DG, Murray LJ. Low-dose aspirin use after diagnosis of colorectal cancer does not increase survival: a case–control analysis of a population-based cohort. Gastroenterology. 2014;146(3):700–8. e702CrossRefPubMed
21.
22.
go back to reference Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.CrossRefPubMed Lévesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ. 2010;340:b5087.CrossRefPubMed
24.
go back to reference Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–9.CrossRefPubMed Suissa S. Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf. 2007;16(3):241–9.CrossRefPubMed
25.
go back to reference Nam CM, Zelen M. Comparing the survival of two groups with an intermediate clinical event. Lifetime Data Anal. 2001;7(1):5–19.CrossRefPubMed Nam CM, Zelen M. Comparing the survival of two groups with an intermediate clinical event. Lifetime Data Anal. 2001;7(1):5–19.CrossRefPubMed
26.
go back to reference Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53.CrossRefPubMed Suissa S. Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease: immortal time bias in observational studies. Am J Respir Crit Care Med. 2003;168(1):49–53.CrossRefPubMed
27.
go back to reference Samet JM: Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! In.: Am Thoracic Soc; 2003. Samet JM: Measuring the effectiveness of inhaled corticosteroids for COPD is not easy! In.: Am Thoracic Soc; 2003.
28.
go back to reference Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol. 2005;115(4):714–9.CrossRefPubMed Suissa S, Ernst P. Bias in observational study of the effectiveness of nasal corticosteroids in asthma. J Allergy Clin Immunol. 2005;115(4):714–9.CrossRefPubMed
29.
go back to reference Mi X, Hammill BG, Curtis LH, Lai ECC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016;35(26):4824–36.CrossRefPubMed Mi X, Hammill BG, Curtis LH, Lai ECC, Setoguchi S. Use of the landmark method to address immortal person-time bias in comparative effectiveness research: a simulation study. Stat Med. 2016;35(26):4824–36.CrossRefPubMed
30.
go back to reference Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299–314. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat. 1996;5(3):299–314.
31.
go back to reference Han E, Jang S-Y, Kim G, Lee Y-h, Choe EY, Nam CM, Kang ES. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine. 2016;95(6):e2786. Han E, Jang S-Y, Kim G, Lee Y-h, Choe EY, Nam CM, Kang ES. Rosiglitazone use and the risk of bladder cancer in patients with type 2 diabetes. Medicine. 2016;95(6):e2786.
32.
go back to reference Kim G, Jang SY, Han E, Lee Y. Park Sy, Nam CM, Kang ES: Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int J Cancer. 2017;140(4):798–806.CrossRefPubMed Kim G, Jang SY, Han E, Lee Y. Park Sy, Nam CM, Kang ES: Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study. Int J Cancer. 2017;140(4):798–806.CrossRefPubMed
33.
go back to reference SAS Institute Inc. Base SAS® 9.4 procedures guide: statistical procedures. Cary: SAS Institute Inc; 2014. SAS Institute Inc. Base SAS® 9.4 procedures guide: statistical procedures. Cary: SAS Institute Inc; 2014.
34.
go back to reference Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34(1):70–85.CrossRef Van Houwelingen HC. Dynamic prediction by landmarking in event history analysis. Scand J Stat. 2007;34(1):70–85.CrossRef
35.
go back to reference Nicolaie M, Houwelingen J, Witte T, Putter H. Dynamic prediction by landmarking in competing risks. Stat Med. 2013;32(12):2031–47.CrossRefPubMed Nicolaie M, Houwelingen J, Witte T, Putter H. Dynamic prediction by landmarking in competing risks. Stat Med. 2013;32(12):2031–47.CrossRefPubMed
36.
go back to reference Klein JP, Moeschberger ML: Survival analysis: techniques for censored and truncated data: Springer Science & Business Media; 2005. Klein JP, Moeschberger ML: Survival analysis: techniques for censored and truncated data: Springer Science & Business Media; 2005.
Metadata
Title
Statistical methods for elimination of guarantee-time bias in cohort studies: a simulation study
Authors
In Sung Cho
Ye Rin Chae
Ji Hyeon Kim
Hae Rin Yoo
Suk Yong Jang
Gyu Ri Kim
Chung Mo Nam
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Medical Research Methodology / Issue 1/2017
Electronic ISSN: 1471-2288
DOI
https://doi.org/10.1186/s12874-017-0405-6

Other articles of this Issue 1/2017

BMC Medical Research Methodology 1/2017 Go to the issue